Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2

Clinical Cancer Research

Volumn 10, Issue 17, 2004, Pages 5650-5655

  Gennari, Roberto ^a   Menard, Sylvie ^b   Fagnoni, Francesco ^c   Ponchio, Luisa ^c   Scelsi, Mario ^c   Tagliabue, Elda ^b   Castiglioni, Fabio ^b   Villani, Laura ^c   Magalotti, Cesare ^c   Gibelli, Nadia ^c   Oliviero, Barbara ^c   Ballardini, Bettina ^c   Da Prada, Gianantonio ^c   Zambelli, Alberto ^c   Costa, Alberto ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA ANTIGEN CLASS 1; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER SURGERY; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TUMOR BIOPSY;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; LYMPHOCYTES; NEOADJUVANT THERAPY; PILOT PROJECTS; PREOPERATIVE CARE; RECEPTOR, ERBB-2; REMISSION INDUCTION;

EID: 4444372733     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0225     Document Type: Article

References (14)

1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
3. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003;21:46-53.
4. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002;38:1817-23.
5. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6.
6. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (Lond) 2002;416:279-80.
7. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
8. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (Bethesda) 2000;92:205-16.
9. Toth J, Kubes M. Masking of HLA class I molecules expressed on K-562 target cells can restore their susceptibility to NK cell cytolysis. Immunobiology 1993;188:134-44.
10. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res 2002;62:6891-900.
11. Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J Virol 2003;77:11158-69.
12. Gudmundsdottir I, Ogmundsdottir HM. Variable natural killer function of tumour-infiltrating lymphocytes from breast carcinomas. APMIS 1992;100:737-46.
13. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21-7.
14. Fleming GF, Meropol NJ, Rosner GL, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res 2002;8:3718-27.